SCHEMBL3971444

SCHEMBL3971444

CC(=O)Oc1ccc(S(=O)(=O)N(C(C)=O)c2ccc(NC(=O)c3cc(-c4ccc(OC(F)F)cc4)oc3C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
MAPT P10636 6/20 0.46
HPGD P15428 3/20 0.46
MEN1 O00255 7/20 0.45
KMT2A Q03164 7/20 0.45
TDP1 Q9NUW8 3/20 0.45
CYP1A2 P05177 2/20 0.45
POLB P06746 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALOX12 P18054 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 2/20 0.40
HSD17B10 Q99714 2/20 0.38
TP53 P04637 1/20 0.37
PTGER4 P35408 2/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3971437 0.82 PTGER4 (0.46) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL3970052 0.74 ALDH1A1 (0.58) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL13716417 0.74 ALDH1A1 (0.50) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5987767 0.73 PTGER4 (0.47) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL3972201 0.72 ALDH1A1 (0.53) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5983659 0.69 PTGER4 (0.49) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5984167 0.68 ALDH1A1 (0.46) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL3978878 0.68 NPC1 (0.61) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5984689 0.68 PTGER4 (0.45) ALDH1A1MAPTHPGDMEN1KMT2A
SCHEMBL5121743 0.68 ALDH1A1 (0.51) ALDH1A1MAPTHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569602-B2 Furan derivatives as EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2009-08-04 US disclosed
EP-1673360-B1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LTD (GB) 2008-12-17 EP disclosed
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2008-12-11 US disclosed
US-7417068-B2 EP4 receptor antagonists ASTERAND UK LIMITED (GB) 2008-08-26 US disclosed
EP-1673360-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2006-06-28 EP disclosed
US-20050124676-A1 EP4 receptor antagonists ASTERAND UK ACQUISITION LIMITED (GB) 2005-06-09 US disclosed
WO-2005037812-A1 FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS ASTERAND UK LIMITED (GB) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124676-A1 EP4 receptor antagonists PTGER4, PTGER3, NR4A3 ALDH1A1 2257/4885MAPT 4666/4885HPGD 1200/4885
US-20080306117-A1 EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER3, NR4A3 ALDH1A1 2257/4885MAPT 4666/4885HPGD 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.